TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Pathologically confirmed acute myeloid leukemia or acute lymphoblastic leukemia:~  * Relapsed \>= 1 time OR refractory disease:~    * Patients who fail primary induction therapy or who relapse after achieving complete remission are eligible if they have received =\< 3 prior courses of induction/reinduction therapy~* Relapsed \>= 1 time OR refractory disease~* Patients who fail primary induction therapy or who relapse after achieving complete remission are eligible if they have received =\< 3 prior courses of induction/reinduction therapy~* No active CNS leukemia~* ECOG performance status 0-2~* AST and ALT =\< 5 times upper limit normal (ULN)~* Alkaline phosphatase =\< 5 times ULN~* Bilirubin =\< 2.0 mg/dL~* Creatinine =\< 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* LVEF \>= 45% by MUGA or ECHO~* No active, uncontrolled infection~* No other life-threatening illness~* No mental deficits and/or psychiatric history that would preclude study compliance~* No active graft-vs-host disease~* Recovered from all prior therapies~* At least 24 hours since prior hydroxyurea, steroids, imatinib mesylate, arsenic trioxide, interferon, or leukapheresis for blast count control~* At least 4 weeks since prior stem cell transplantation (autologous or allogeneic)~* At least 4 days since prior growth factors~* At least 3 weeks since prior chemotherapy, except for non-aplasia producing treatments (e.g., low-dose cyclophosphamide, hydroxyurea, interferon, imatinib mesylate, mercaptopurine, thalidomide, azacitidine, or decitabine)~* No prior flavopiridol~* No other concurrent chemotherapy, radiotherapy, or immunotherapy~* No acute promyelocytic leukemia (M3)~* No hyperleukocytosis with \> 50,000 blasts/mm\^3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive flavopiridol IV over 30 minutes on days 1, 2, and 3. Patients receive cytarabine IV continuously over 72 hours beginning on day 6 and mitoxantrone hydrochloride IV over 60-120 minutes on day 9.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Safety of Alpha1-Proteinase Inhibitor (Human) in Japanese Subjects With Alpha1 Antitrypsin Deficiency (GTI1401-OLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who complete participation in Study GTI1401 (i.e., have completed the study through the Week 9 Visit).~* Subjects who will and are able to provide written informed consent.~Exclusion Criteria:~* Subjects with newly diagnosed severe concomitant disease including, but not limited to, congestive heart failure and liver cirrhosis.~* Subjects with newly diagnosed malignant tumor (including malignant melanoma; however, other forms of skin cancer are allowed).~* Female subjects who are pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or abstinence) throughout the study or male subjects who have a partner who is of child-bearing potential and is unwilling to practice a highly effective method of contraception throughout the study.~* Subjects with clinical signs and symptoms of active hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) viral infection at the Week 9 Visit of Study GTI1401 and viral infection is further confirmed by testing.~* Subjects with current evidence of smoking or has a positive urine cotinine test at the Week 9 Visit in Study GTI1401 that is due to smoking.~* Subjects who currently participate in a study of another investigational product (other than Alpha-1 MP).~* Subjects who have difficulty in adhering to the protocol or its procedures, in the opinion of the investigator.~* Subjects who have medical conditions that may confound the results of this clinical trial or may endanger these subjects during their participation in this clinical trial in the opinion of the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Alpha-1 MP (Type: EXPERIMENTAL): Participants received IV infusion of 60 mg/kg Alpha-1 MP administered weekly for mean duration of 213 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Must be 18 years of age or older~2. Diagnosis of open primary angle glaucoma(POAG) or ocular hypertension (OHT) in both eyes~3. Unmedicated intraocular pressure (IOP) \>20 mmHg and \< 30 mmHg in both eyes at first qualification visit~4. Best corrected visual acuity (BCVA) equivalent to 20/200 Snellen or better~5. Able to give informed consent and follow study instructions~Exclusion Criteria:~Ophthalmic:~1. Clinically significant ocular disease~2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure glaucoma, or narrow angles~3. Intraocular pressure ≥30 mmHg in either eye~4. A difference in IOP between eyes \>4mmHg at qualification visit~5. Use of more than two ocular hypotensive medications within 30 days of screening~6. Known hypersensitivity to any component of the formulation~7. Previous glaucoma surgery or refractive surgery~8. Keratorefractive surgery in either eye~9. Report of ocular injury in either eye within the six months prior to screening or ocular or non-refractive surgery within 3 months prior to screening~10. Recent or current ocular infection or inflammation in either eye~11. Use of ocular medication in either eye of any kind within 30 days of screening~12. Mean central corneal thickness greater than 620 μm in either eye~13. Any abnormality preventing reliable applanation tonometry of either eye~14. Lack of suitable episcleral vein prior to performing Episcleral Venus Pressure (EVP) measurement (applicable to 1 site only)~    Systemic:~15. Clinically significant abnormalities within 6 weeks prior to screening~16. Clinically significant systemic disease~17. Participation in any investigational study within 60 days prior to screening~18. Use of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening~19. Women of childbearing potential who were pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Netarsudil Ophthalmic Solution 0.02% (Type: EXPERIMENTAL): Netarsudil Ophthalmic Solution 0.02% was administered in one eye and Placebo comparator in contralateral eye
- Placebo Comparator (Type: PLACEBO_COMPARATOR): Placebo comparator administered in one eye and Netarsudil Ophthalmic Solution 0.02% in contralateral eye

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Active Tymbion Iontophoresis to Sham Tymbion Iontophoresis for Anesthesia of the Tympanic Membrane

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion/Exclusion Criteria~Inclusion Criteria Group A:~1. Healthy adults, 18-50 years old~2. Subject is able and willing to comply with the protocol and attend all study visits~3. Subject is able and willing to provide informed consent~4. Subjects with air conduction hearing thresholds of 25 dB HL or better at standard frequencies up to 2000 Hz, and 45 dB or better at 4000 Hz.~5. Subject is able to read and understand English~Exclusion Criteria Group A:~1. Pregnant or lactating females.~2. Prior ear iontophoresis procedure~3. Subjects with conductive hearing loss.~4. Subjects with history of sensitivity or allergic reaction to lidocaine HCl, tetracaine, epinephrine, or any hypersensitivity to local anesthetics of the amide type, or any component of the anesthetic drug formulation.~5. Familial history of insensitivity to lidocaine or other local anesthetics of the amide type.~6. Significantly atrophic, retracted, bimeric, monomeric or atelectatic tympanic membrane.~7. Perforated tympanic membrane.~8. Subjects with known history of ear surgery or TM condition that has the potential to affect the sensitivity of the TM~9. Otitis externa.~10. Damaged/denuded skin in the auditory canal.~11. Subjects with electrically sensitive support systems~12. Cerumen impaction resulting in a significant amount of cleaning required to visualize the tympanic membrane.~13. Evidence of Otitis Media at day of procedure, or within the past three (3) months prior to procedure.~14. Other conditions that would preclude performing the study procedure including ear plug incompatibility.~15. Health conditions that, in the opinion of the investigator, would present undue risk to the subject, based on device/anesthetic drug product label warnings and precautions.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Active Tymbion Iontophoresis (Type: EXPERIMENTAL): Unilateral treatment with active iontophoresis of Tymbion (2% lidocaine HCl/ 1:100,000 epinephrine) using the Tusker Medical Tula Iontophoresis System.
- Sham Tymbion Iontophoresis (Type: SHAM_COMPARATOR): The sham iontophoresis procedure will be identical to the active Tymbion iontophoresis in that Tymbion (2% lidocaine/ 1:100,000 epinephrine solution) will be placed in the external ear canal, however the iontophoresis current delivery (which facilitates penetration of drug into the tympanic membrane tissue) will not be activated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lymph Node Mapping in Patients With Endometrial Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The patient must be willing and able to provide informed consent~* The patient is willing and able to comply with the study protocol~* The patient has endometrial cancer and is scheduled for robotic hysterectomy and lymphadenectomy~* The patient agrees to follow-up examinations out to 5-years post-treatment~Exclusion Criteria:~* The patient is not a candidate for robotic assisted hysterectomy and lymphadenectomy~* The patient has known or suspected allergies to iodine, indocyanine green (ICG) or isosulfan blue (ISB)~* The patient has hepatic dysfunction confirmed by bilirubin \> 2 x normal (based on reference values from the laboratory used by the patient)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- sentinel lymph node detection (Type: EXPERIMENTAL): Patients undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue and sentinel lymph node biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Osimertinib Study in Indian Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient of either gender and ≥18 years of age~2. Patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an appropriate test, who have progressed on or after EGFR TKI therapy by an independent clinical judgment of treating physician based on locally approved prescribing information~3. Each patient must sign an informed consent form (ICF)~Exclusion Criteria:~1. Patient with either the history of hypersensitivity to excipients of the study drug or to drugs with a similar chemical structure or class to the study drug.~2. Pregnant and/or lactating women~3. Patients participating in any current or future interventional trial will not be enrolled in the current study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Single (Type: EXPERIMENTAL): Single arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase II/III Trial of CPT-11/5-FU/l-LV Versus CPT-11/TS-1 as Second Line Chemotherapy of Unresectable Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed colorectal cancer~* Locally advanced and/or metastatic colorectal cancer~* Have prior chemotherapy as first line treatment~* No prior irinotecan administration~* Able to take oral medication~* Age 20 to 75~* Performance status 0 or 1 (ECOG)~* WBC 3,000-12,000 / mm\^3~* Platelet ≥100,000 / mm\^3~* AST and ALT ≤ 100 IU/L~* Creatinine ≤ 1.2 mg/dL~* Bilirubin ≤ 1.5 mg/dL~Exclusion Criteria:~* Prior radio therapy for colorectal cancer~* Other malignancies in the past 5 years~* Serious illness or medical condition

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CPT-11 and TS-1
- 2 (Type: ACTIVE_COMPARATOR): CPT-11, 5-FU and l-LV

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month-old infants~* Available for the entire study period~Exclusion criteria:~* Previous vaccination with any vaccine before the start of the study~* Known contraindication to vaccination

- Gender: ALL
- Minimum Age: 42 Days
- Maximum Age: 98 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
1. Individuals without Laryngectomy (Controls)~   Inclusion Criteria:~  * Primary English speaker~  * No history of speech, language, cognitive, or hearing disorders~  * Normal hearing (able to pass a bilateral hearing screening using a threshold of 25 decibels (dB) hearing level (HL) at 125, 250, 500, 1000, 2000, 4000, and 8000 Hz based on the American Speech-Language-Hearing Association)~  * Capable of signed informed consent~   Exclusion Criteria:~  * Inability to understand spoken English or follow simple instructions~  * History of speech, language, cognitive, or hearing disorders~  * Inability to provide written informed consent~2. Individuals with Laryngectomy~Inclusion Criteria:~* At least 6 months S/P total laryngectomy~* Primary English speaker~* Proficient with an electrolarynx (EL)~* Sufficiently available and healthy to comply with multiple test sessions lasting 4-6 hours~* Capable of signed informed consent~Exclusion Criteria:~* Inability to understand spoken English or follow simple instructions~* Loss of adequate surface electromyographic (sEMG) sensor sites for recording from muscles of articulation due to cancer treatment~* Skin disorders or radiation/surgical scarring that prevent the use of medical-grade adhesive tapes for securing sensors~* Any other medical or psychological condition that is based on the opinion of investigations will prevent participation in the experiment (e.g., the candidate may have an illness that makes them fatigue easily or have difficulty to attend to visual cues)~* Inability to provide written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental and Reference Devices for Communication (Type: EXPERIMENTAL): Each participant listens to speech produced by an experimental (MyoVoice) and reference (electrolarynx) systems that are used to communicate. Participants rate the naturalness of the speech produced from each device (audio files presented in a randomized order). Duration: 30 mins to 1 hour.
- Development of Speech Corpora (Type: NO_INTERVENTION): Each participant produces a list of speech tasks that include syllables, phrases, reading passages, and open-ended questions using the MyoVoice system. Myovoice pitch and loudness recognition accuracy of speech is evaluated. Duration: 30 mins to 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ringer's Lactate Versus Normal Saline in Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All parturients who consent for the study.~* Up to American Society of Anesthesiology (ASA) class ІІ/E.~Exclusion Criteria:~* Failed spinal anaesthesia that has to be converted to general anaesthesia.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Normal Saline (Type: ACTIVE_COMPARATOR): 250 patients in this arm assigned to receive normal saline as the study fluid
- Ringer's Lactate (Type: ACTIVE_COMPARATOR): 250 patients in this arm assigned to receive Ringer's Lactate as the study fluid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Previously treated with a sulfonylurea for at least 3 months~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious cardiovascular complications~* Evidence of serious diabetic complications~* Laboratory value abnormalities as defined by the protocol~* Known sensitivity to glimepiride~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- LAF237 50 mg qd + glimepiride 4 mg qd (Type: EXPERIMENTAL): LAF237 50 mg qd + glimepiride 4 mg qd
- LAF237 50 mg bid + glimepiride 4 mg qd (Type: EXPERIMENTAL): LAF237 50 mg bid + glimepiride 4 mg qd
- LAF237 placebo + glimepiride 4 mg qd (Type: PLACEBO_COMPARATOR): LAF237 placebo + glimepiride 4 mg qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rotavirus Efficacy and Safety Trial (REST)(V260-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy infants~Exclusion Criteria:~* None Specified

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): RotaTeq
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Preserved)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 or above~* Congestive Heart Failure with symptoms for more than 4 weeks before starting study~* Provision of informed consent~Exclusion Criteria:~* Current low blood pressure with symptoms~* Liver disease considered significant by the study doctor~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete